Studies Indicate Progress, Highlight Challenges of Combating Lung Cancer Stigma
Cody HoltData presented by patient advocate Jill Feldman and Nathan Harrison show that while the IASLC’s Language Guide is helping to reduce the use of stigmatizing language, research on the effects of stigma in lung cancer is lacking. Read more
Closing Plenary Aims to Close the Gap Between Neoadjuvant IO, Pathology
Fred GebhartDrs. Keith Kerr and Sanja Dacic will examine the role of pathology in patient selection and specimen interpretation in the era of neoadjuvant immunotherapy. Read more
Plenary Session to Offer Strategies for Overcoming Barriers in Transforming Discoveries into Treatments in Lower, Middle-Income Regions
Fred GebhartCo-chair Dr. Pyng Lee said simply because a treatment has been approved does not make it an affordable and accessible clinical alternative for lung cancer patients in the real world. Read more
Successful Lung Cancer Screening Programs Must Consider Unique Needs of Region, Population
Fred GebhartDrs. Claudia Henschke and Pan-Chy Yang to chair an education session designed to help thoracic oncologists translate research into successful lung cancer screening efforts. Read more
Educational Session to Provide Update on Recent Progress in Treatment of ‘Extensive-Stage’ SCLC
Fred GebhartDrs. Hidehito Horinouchi and Stephen Liu will chair the session, which will explore multiple advances driving survival gains, including antibody-drug conjugates, bispecific T-cell engagers, and targeted therapies. Read more
New Strategic Plan to be Unveiled at IASLC Business Meeting
Erin JungmeyerMembers are invited to join the meeting and learn about the new plan, which will guide the association for the next 5 years. Read more
Opening Plenary Session Examines Treatment Inequities, Humanitarian Toll of Lung Cancer
Cody HoltIn addition to thought-provoking keynotes from Her Royal Highness Princess Dina Mired and Dr. Gary Rodin, the official kickoff of #WCLC23 included a lively celebration of the meeting’s host city. Read more
Novel Immunochemotherapy / Anti-Angiogenesis Combo Shows Best Survival to Date for ES-SCLC
Fred GebhartInvestigator Dr. Ying Cheng says study results support the use of immunochemotherapy plus anti-angiogenesis as a new treatment option in a difficult-to-treat patient population. Read more
Make time to visit the Exhibit Hall this evening to talk with poster presenters about their research. Read more
Presidential Symposium to Highlight Late-Breaking, Practice-Changing Research
Fred GebhartThe symposium also marks a change in IASLC leadership as Dr. Heather Wakelee will deliver the final Presidential Address of her term. Read more